Abstract
Liver ischemia-reperfusion injury (IRI) serves as a critical pathological basis for post-hepatectomy liver failure and graft dysfunction following liver transplantation. Excessive inflammatory responses, oxidative stress, and cell death are key mechanisms underlying IRI. The lack of multi-targeted therapies contributes to the current insufficiency in clinical IRI management. This study developed endothelial-targeting VHPKQHR peptide (VHP)-modified ginseng-derived exosomes (G-Exos) loaded with IL-6 small interfering RNA (Si-IL6) (siRNA@VG-Exos) to mitigate liver IRI. VHP modification facilitated the targeted delivery of siRNA@VG-Exos to damaged endothelium, promoting their accumulation and subsequent release at the IRI site. siRNA@VG-Exos effectively reduced hepatic inflammatory cytokine release, enhanced T-SOD and CAT expression while suppressing MDA generation, thereby alleviating oxidative stress. Furthermore, they promoted the restoration of mitochondrial membrane potential, maintaining mitochondrial homeostasis. Si-IL6 additionally suppressed IL-6 expression in liver tissue, synergistically enhancing the anti-inflammatory effect of G-Exos. Moreover, siRNA@VG-Exos inhibited CD86 expression and promoted CD206 expression in hepatic macrophages, facilitating their polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype and modulating immunity. Ultimately, siRNA@VG-Exos reduced hepatic necrotic areas, lowered ALT and AST levels, and restored liver tissue function. Further sequencing analysis indicated that siRNA@VG-Exos alleviates liver IRI by inhibiting immune and inflammatory responses and oxidative stress damage. Therefore, siRNA@VG-Exos provides a novel targeted strategy for the treatment of liver IRI.
Graphical Abstract

This study developed endothelial-targeting VHPKQHR peptide (VHP)-modified ginseng-derived exosomes (G-Exos) loaded with IL-6 small interfering RNA (Si-IL6) (siRNA@VG-Exos) to mitigate liver IRI. siRNA@VG-Exos provides a novel targeted strategy for the treatment of liver IRI.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12951-025-03954-2.
Keywords: Liver ischemia-reperfusion injury, Ginseng-derived exosomes, Hepatic macrophages, Inflammatory response, Oxidative stress
Introduction
Hepatic ischemia-reperfusion injury (IRI) is a clinically common complication. It frequently occurs after partial hepatectomy, following liver transplantation, and during hemorrhagic shock [1]. This injury is a major contributor to postoperative liver dysfunction after partial hepatectomy, and is associated with increased rates of early graft dysfunction and failure. Although significant progress has been made in understanding the mechanisms of hepatic IRI in recent years, the lack of effective translational measures means liver IRI remains a critical risk factor for postoperative complications and liver graft dysfunction. Consequently, developing new therapeutic strategies to mitigate hepatic ischemia-reperfusion injury is an urgent research priority [2–4].
The mechanisms underlying hepatic ischemia-reperfusion injury primarily involve microcirculatory dysfunction, hypoxia, metabolic disturbances, oxidative stress, innate immune responses, adaptive immunity, and cell death signaling [5]. This injury is characterized by two interconnected phases: the ischemic phase causing hepatocyte damage and the release of damage-associated molecular patterns (DAMPs), followed by the recruitment of immune cells triggering an inflammatory cascade that further damages hepatocytes [5, 6]. Macrophages play a crucial role in this inflammatory cascade and subsequent hepatocyte injury. Research indicates that HO-1 regulates macrophage activation and modulates hepatocyte death in hepatic IRI via the SIRT1-p53 signaling network [7]. Similarly, the Ninj1/DUSP1 axis promotes hepatic IRI by regulating macrophage activation [8]. Conversely, expression of HSPA12A in hepatocytes suppresses macrophage chemotaxis and activation, thereby inhibiting the subsequent inflammatory cascade and ultimately protecting against IRI [5]. Liver macrophages can polarize into distinct functional phenotypes: classically activated (M1) macrophages, which secrete pro-inflammatory cytokines like IL-6 and TNF-α, and alternatively activated (M2) macrophages, which exhibit anti-inflammatory properties [9, 10]. Consequently, macrophage polarization significantly influences the severity of hepatic IRI, and reducing macrophage-mediated inflammation is beneficial for mitigating this injury.
Exosomes represent an emerging therapeutic approach for ameliorating hepatic ischemia-reperfusion injury [11]. Their efficacy has been demonstrated in various animal models. Due to their low immunogenicity, exosomes can transport diverse bioactive components, thereby modulating immune responses, suppressing inflammation, and ultimately promoting repair in injured organs [12]. Notably, mesenchymal stem cell (MSC)-derived exosomes can mitigate ischemia-reperfusion injury by inhibiting the activation of multiple pro-inflammatory cells, reducing the secretion of inflammatory cytokines, and promoting anti-inflammatory cells such as M2 macrophages [13–15]. Studies indicate that MSC-derived exosomes reduce CD154 expression on CD4 + T cells, thereby alleviating hepatic IRI [16]. Natural herbal components can also attenuate hepatic IRI through multiple mechanisms [17]. Panax ginseng, a valued herb in traditional Chinese medicine, contains ginsenosides as its principal bioactive constituents. Ginsenosides can prevent hepatic IRI through their anti-inflammatory, antioxidant, and anti-apoptotic properties; for instance, they inhibit cytokine production and immune cell infiltration by modulating STAT3 and NF-κB signaling and upregulating Nrf2 [18]. Given this background, it is plausible that ginseng-derived exosomes (G-Exos) contain multiple bioactive compounds capable of modulating inflammation and immunity, suggesting potential for disease treatment, particularly in injury repair [19]. G-Exos have attracted significant interest due to their excellent biocompatibility, stability, and potent bioactivity. They have been reported to improve skin wound healing and enhance tumor cell immunotherapy [20]. Thus, ginseng-derived exosomes hold promise as a novel therapeutic strategy for alleviating hepatic ischemia-reperfusion injury.
Small interfering RNA (siRNA) consists of double-stranded RNA molecules, typically 20–25 nucleotides in length. It regulates gene expression by binding to target mRNA, leading to its degradation by cellular nucleases (e.g., within the RISC complex), thereby preventing mRNA translation [21]. Within the inflammatory cascade triggered by hepatic ischemia-reperfusion injury, the release of the cytokine IL-6 plays a significant role. Utilizing IL-6-specific siRNA (si-IL6) to block IL-6 synthesis can reduce the release of inflammatory cytokines and mitigate macrophage-mediated inflammation [22, 23].However, naked siRNA faces significant delivery challenges: it cannot passively diffuse into cells efficiently, is rapidly degraded by enzymes in plasma and cleared by the kidneys, has limited permeability across capillary endothelium, and exhibits poor uptake efficiency by target cells [21, 22, 24]. Utilizing exosomes as siRNA carriers can enhance cellular uptake due to their intrinsic properties and improve stability owing to their biocompatibility, reducing premature clearance The VHPKQHR peptide (VHP) targets vascular cell adhesion molecule 1 (VCAM1), which is expressed on activated endothelial cells in inflamed vasculature [25, 26]. Studies indicate that nanoparticles modified with endothelial-targeting peptides exhibit enhanced affinity for VCAM1 at sites of significant damage, enabling targeted delivery to inflamed areas such as those in rheumatoid arthritis and atherosclerosis, thereby improving their diagnostic and therapeutic efficacy [27, 28]. Therefore, modifying exosomes with the VHP endothelial-targeting peptide (VHP-exosomes) may promote their accumulation at sites of liver injury, enhancing therapeutic potential.
This study developed VHP-targeted peptide-modified ginseng-derived extracellular vesicles loaded with IL-6 siRNA (siRNA@VG-Exos) to mitigate hepatic ischemia-reperfusion injury (Scheme 1). The VHP-targeting peptide modification promotes enhanced accumulation of siRNA@VG-Exos within the vascular endothelium of injured liver tissue, strengthening endothelial adhesion and facilitating both the effective accumulation and subsequent release of the si-IL6-loaded G-Exos. G-Exos contribute to protection by reducing oxidative stress damage, inhibiting the release of inflammatory cytokines, suppressing M1 macrophage polarization, and stabilizing mitochondrial function, thereby exerting anti-inflammatory, antioxidant, and metabolic regulatory effects. Additionally, si-IL6 further suppresses the expression of the core inflammatory cytokine IL-6 in liver tissue, synergistically inhibiting the inflammatory response. Collectively, siRNA@VG-Exos promote the repair of damaged liver tissue in IRI, offering a novel therapeutic strategy for clinical conditions such as post-hepatectomy liver failure and post-transplantation graft dysfunction.
Fig. 1.
siRNA@VG-Exos Alleviates Hepatic Ischemia-Reperfusion Injury (IRI). Modification with the VHP-targeting peptide enhances the accumulation of siRNA@VG-Exos at sites of liver injury, thereby effectively promoting the release of both siRNA and G-Exos. This process reduces inflammatory responses and oxidative stress, facilitates the restoration of mitochondrial homeostasis, and induces the polarization of macrophages toward the anti-inflammatory M2 phenotype, ultimately alleviating liver injury
Result
Synthesis and characterization of siRNA@VG-Exos
G-Exos were isolated and purified via density gradient centrifugation (Fig. 2A). IL-6-targeting siRNA was electroporated into G-Exos to generate siRNA@G-Exos, followed by incubation with the endothelial-targeting peptide VHPKQHR (VHP) to form siRNA@VG-Exos. The siRNA loading efficiency, quantified using a RiboGreen assay, demonstrated that electroporation achieved an encapsulation efficiency of approximately 89%. The release kinetics of the encapsulated siRNA exhibited remarkable temperature dependence: incubation at 37 °C accelerated siRNA release, while 4 °C maintained long-term stability and effectively delayed the release process. Furthermore, in vitro release kinetics experiments confirmed the sustained-release characteristics of the siRNA@VG-Exos delivery system (Supplementary Fig. 1). Transmission electron microscopy (TEM) revealed that G-Exos, siRNA@G-Exos, and siRNA@VG-Exos exhibited an elliptical, cup-shaped morphology with a bilayer membrane structure and diameters of approximately 100 nm (Fig. 2B). Nanoparticle tracking analysis (NTA) confirmed a size distribution of 50–200 nm and a peak diameter of 100 nm, validating successful exosomes isolation (Fig. 2C-E). Zeta potential measurements indicated potentials below − 20 mV for all three constructs, demonstrating high stability (Fig. 2F). siRNA@VG-Exos maintained consistent particle sizes over 7 days at both 4 °C and 37 °C, further confirming their robust stability (Fig. 2G).
Fig. 2.
Preparation, Characterization, and Stability Assessment of siRNA@VG-Exos. (A) Schematic diagram of G-Exos isolation. (B) Representative transmission electron microscopy (TEM) images of G-Exos, siRNA@G-Exos, and siRNA@VG-Exos. (C-E) Nanoparticle tracking analysis (NTA) size distribution profiles of G-Exos, siRNA@G-Exos, and siRNA@VG-Exos. (F) Zeta potential measurements of G-Exos, siRNA@G-Exos, and siRNA@VG-Exos.(G) Particle size stability of siRNA@VG-Exos monitored by NTA at 4 °C and 37° Cover 7 days. (H) Ginsenoside composition in siRNA@VG-Exos. (I) Expression heatmap of top 50% miRNAs in siRNA@VG-Exos samples. (J) KEGG enrichment of miRNA targets highlighting key pathways
We analyzed the ginsenoside composition in G-Exos and Our analysis confirmed the presence of multiple bioactive ginsenosides in G-Exos, including Re, Rg1, Rf, F1, Rh2, CK, Rg3, and F2 (Fig. 2H). Small RNA sequencing revealed that G-Exos are enriched with specific functional miRNAs (Fig. 2I-J). Bioinformatic analyses indicated that their predicted target genes are significantly associated with anti-inflammatory and antioxidant processes, and are enriched in key pathways such as PI3K-Akt and Hippo signaling (Fig. 2I-J). GO enrichment analysis revealed that the predicted target genes of G-Exos miRNAs were significantly enriched in biological processes including “negative regulation of inflammatory response,” “response to oxidative stress,” and “regulation of cell proliferation,” (Supplementary Fig. 2) thereby systematically linking the molecular composition of G-Exos to its observed anti-inflammatory, antioxidant, and pro-proliferative phenotypic outcomes. This establishes a molecular basis for the intrinsic bioactivity of G-Exos.
To evaluate the effect of temperature on the stability of siRNA encapsulated in VG-Exos, we compared its release behavior in PBS at 4 °C and 37 °C. As shown in Supplementary Fig. 1, siRNA release at 4 °C was slow and sustained, indicating that the carrier system effectively maintains long-term stability of the encapsulated content. In contrast, release at 37 °C exhibited typical biphasic characteristics: a rapid initial release phase within the first 0–2 days, followed by a significantly slower release rate. The cumulative release at 37 °C was significantly higher than that at 4 °C at all time points, confirming that the release process is clearly temperature-dependent (Supplementary Fig. 1).
We next evaluated the in vivo gene silencing efficacy of siRNA@VG-Exos in a murine model of hepatic IRI. Administration of siRNA@VG-Exos resulted in a dose-dependent reduction of IL-6 mRNA levels in liver tissues (across a dose range of 0.1–2.1 mg/kg). A significant knockdown effect was observed at a dose of 0.5 mg/kg at 6 h post-administration compared to lower dose groups (Supplementary Fig. 3 A). A time-course study following a single intravenous injection of 0.5 mg/kg further demonstrated that the gene silencing effect against IL-6 was progressively enhanced over 12 h (Supplementary Fig. 3B).
SiRNA @VG-Exos mitigate hypoxia/reoxygenation (H/R)-induced macrophage injury
Incubation of macrophages with Dio-labeled siRNA@VG-Exos demonstrated efficient cellular uptake by flow cytometry (Fig. 3A). Hypoxia/reoxygenation (H/R) induced oxidative stress through suppressed T-SOD and CAT expression, concomitant with elevated MDA generation and consequent ROS accumulation (Fig. 3B-D). Pretreatment with G-Exos or Si-IL6 attenuated this oxidative damage. Notably, siRNA@VG-Exos significantly restored T-SOD and CAT expression while suppressing MDA and ROS production, indicating potent cytoprotection (Fig. 3B-D). Consistent with oxidative stress profiles, H/R elevated apoptosis (increased Annexin V + cells and JC-1 green monomer-positive cells) and impaired proliferation (reduced BrdU fluorescence). siRNA@VG-Exos stimulation markedly restored macrophage proliferative capacity and reduced apoptosis (Fig. 3E-G).
Fig. 3.
siRNA@VG-Exos Attenuates Oxidative Stress Injury in RAW Cells. (A) Cellular uptake of siRNA@VG-Exos by RAW cells. Flow cytometry analysis of DiO-labeled siRNA@VG-Exos uptake under control (4 °C) or endocytosis inhibitor pretreatment (Filipin 10 µg/mL, Chloroquine 50 µM) conditions. RAW cells were pretreated with si-IL6, G-Exos, or siRNA@VG-Exos prior to H/R. (B-D) ELISA quantification of T-SOD, CAT, and MDA levels. (*p < 0.05 vs. Control; #p < 0.05 vs. H/R; &p < 0.05 vs. H/R + si-IL6; %p < 0.05 vs. H/R + G-Exos; n = 5). (E) Apoptosis analysis by flow cytometry using APC Annexin V and 7-AAD staining. (F) JC-1 staining assessed by flow cytometry: red fluorescence indicates high mitochondrial membrane potential (ΔΨm), green indicates ΔΨm dissipation.(G) Immunofluorescence staining of proliferating RAW cells: BrdU (red), nuclei (DAPI, blue). Scale bar = 50 μm
siRNA@VG-Exos promote macrophage M1-to-M2 polarization to attenuate inflammation
H/R stimulation triggered macrophage polarization toward the M1 phenotype, evidenced by increased CD86 expression. Pretreatment with si-IL6 or G-Exos effectively suppressed CD86 upregulation and enhanced expression of the M2 marker CD206. Notably, siRNA@VG-Exos demonstrated superior efficacy in promoting the M1-to-M2 phenotypic shift (Fig. 4A). Quantitative RT-PCR (qRT-PCR) analysis revealed that siRNA@VG-Exos pretreatment significantly downregulated pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) concomitant with this polarization (Fig. 4B-D). Furthermore, H/R elevated the M1 marker iNOS while suppressing M2 markers (IL-10, Arg1, CD206), confirming M1 polarization. Compared to si-IL6 or G-Exos alone, siRNA@VG-Exos more potently induced M2 anti-inflammatory polarization (Fig. 4E-H).
Fig. 4.
siRNA@VG-Exos Attenuates Inflammation in RAW Cells by Promoting M2 Polarization and Suppressing M1 Polarization. RAW cells were pretreated with si-IL6, G-Exos, or siRNA@VG-Exos prior to H/R. (A) Immunofluorescence staining of M1 marker CD86 (green), M2 marker CD206 (red), and nuclei (DAPI, blue) in RAW cells. Scale bar = 50 μm. (B-D) qRT-PCR analysis of IL-6, TNF-α, and IL-1β mRNA levels (n = 5). (E-H) qRT-PCR analysis of iNOS, IL-10, Arg1, and CD206 mRNA levels. (*p < 0.05 vs. Control; #p < 0.05 vs. H/R; &p < 0.05 vs. H/R + si-IL6; %p < 0.05 vs. H/R + G-Exos; n = 5)
siRNA@VG-ExosTarget injured liver tissue to enhance exosomes accumulation
To evaluate the impact of VHP endothelial-targeting peptide modification on G-Exos accumulation in injured liver, DIR-labeled siRNA@VG-Exos (VHP-modified) and non-targeted siRNA@G-Exos were intravenously administered via tail vein in a murine IRI model. In vivo optical imaging revealed that VHP modification significantly enhanced siRNA@VG-Exos accumulation in ischemic liver tissue within 1 h post-injection. Fluorescence intensity remained substantially higher in the siRNA@VG-Exos group compared to the siRNA@G-Exos group throughout the 1–8 h observation period (Fig. 5A). Ex vivo fluorescence imaging of excised livers further confirmed the specific and robust accumulation of siRNA@VG-Exos in injured hepatic tissue (Fig. 5B, C).
Fig. 5.
Distribution of siRNA@VG-Exos in the liver IRI model. DIR-labeled siRNA@G-Exos or siRNA@VG-Exos were intravenously administered via the tail vein after establishing the mouse IRI model. (A) IVIS images at 0 H, 1 H, 2 H, 4 H, 6 H, and 8 H post-injection. siRNA@G-Exos (top row), siRNA@VG-Exos (bottom row). (B) IVIS images of five major organs (heart, liver, lung, spleen, kidney) collected 8 H post-injection. siRNA@G-Exos (top), siRNA@VG-Exos (bottom). (C) Quantification of fluorescence intensity in the five major organs 8 H post-injection. (Statistical significance: *p < 0.05, n = 3)
Critically, this enhanced accumulation was demonstrated to be VCAM-1-dependent. In animal studies, pre-blocking the VHP peptide on siRNA@VG-Exos with recombinant VCAM-1 protein significantly attenuated liver targeting efficiency, resulting in markedly reduced fluorescence signals in both in vivo and ex vivo imaging (Supplementary Figs. 4 and 5). This provides direct evidence that VHP-VCAM-1 interaction is the primary mechanism mediating the specific accumulation of siRNA@VG-Exos in ischemic liver tissue. And histological analysis indicated substantially weakened improvement in liver injury in the VHP pre-blocking group (Supplementary Fig. 6).
siRNA@VG-Exos ameliorate murine hepatic Ischemia-Reperfusion injury
Mice were administered G-Exos, siRNA@G-Exos, or siRNA@VG-Exos via tail vein injection upon reperfusion following 1 h of hepatic ischemia. Liver tissues were harvested 6 h post-reperfusion (Fig. 6A). H&E staining revealed extensive necrosis and inflammatory infiltration in IRI-injured livers. Both G-Exos and si-IL6 treatment reduced necrotic areas, with siRNA@VG-Exos demonstrating superior therapeutic efficacy (Fig. 6B, C). Biochemical analysis demonstrated that both G-Exos and siRNA@G-Exos significantly attenuated IRI-induced elevation of serum ALT and AST levels compared to the IRI group (Fig. 6D, E). Notably, siRNA@VG-Exos exhibited the most potent suppressive effect on these liver enzymes among all treatment groups, indicating its enhanced hepatoprotective capacity. Furthermore, siRNA@VG-Exos significantly increased Ki67 expression in liver tissue, counteracting IRI-impaired proliferative capacity (Fig. 6F). Assessment of oxidative stress markers demonstrated that IRI severely suppressed hepatic antioxidant activity (T-SOD, CAT) while elevating MDA levels. Notably, siRNA@VG-Exos more potently attenuated these IRI-induced oxidative stress imbalances than other treatments, likely due to enhanced exosomes accumulation at injury sites (Fig. 6G-I).
Fig. 6.
siRNA@VG-Exos alleviates liver ischemia-reperfusion injury in mice. (A) Schematic of the mouse liver ischemia-reperfusion injury (IRI) model. Mice were subjected to 1 h of liver ischemia followed by intravenous administration of PBS, G-Exos, siRNA@G-Exos, or siRNA@VG-Exos. Mice were sacrificed at 2 h after reperfusion. (B) Representative H&E-stained liver sections from different treatment groups. Scale bar = 100 μm (n = 8). (C) Suzuki injury scores of liver sections based on H&E staining (n = 8). (D, E) Serum ALT and AST levels measured using an automated biochemistry analyzer (n = 8). (F) Representative images of Ki-67 immunohistochemical staining in liver sections. Scale bar = 100 μm. (G-I) Levels of MDA, T-SOD, and CAT in liver tissues measured by ELISA. Statistical significance: * vs. control; # vs. IRI; & vs. IRI + G-Exos; % vs. IRI + siRNA@G-Exos (p < 0.05, n = 5)
siRNA@VG-Exos mitigates hepatic IRI through multi-mechanism actions on macrophage polarization, cell death pathways, and endothelial function
Immunofluorescence analysis of liver tissues revealed significantly elevated CD86 expression in hepatic macrophages after IRI, indicating M1 polarization. Compared to G-Exos or siRNA@G-Exos treatment, intravenous administration of endothelial-targeted siRNA@VG-Exos markedly suppressed IRI-induced CD86 expression while enhancing CD206 expression (an M2 macrophage marker), demonstrating superior efficacy in promoting the M1-to-M2 phenotypic shift (Fig. 7A). qRT-PCR analysis confirmed that siRNA@VG-Exos significantly downregulated pro-inflammatory cytokine mRNA expression (IL-6, TNF-α, IL-1β) in IRI-injured livers (Fig. 7B-D). Further assessment of macrophage polarization markers showed IRI robustly upregulated M1 markers (CD80, CD86) while suppressing M2 markers (CD206, Arg1, IL-10). Consistent with immunofluorescence data, siRNA@VG-Exos more potently reversed this polarization imbalance toward an M2-dominant phenotype than other treatments (Fig. 7E-I).
Fig. 7.
siRNA@VG-Exos alleviates inflammation in mouse liver ischemia-reperfusion injury by promoting M2 macrophage polarization and inhibiting M1 polarization. (A) Representative triple immunofluorescence staining of liver sections for CD206 (red), CD86 (green), and DAPI (blue). Scale bar = 100 μm. (B-D) Levels of IL-6, TNF-α, and IL-1β mRNA in liver tissues measured by quantitative real-time PCR (qRT-PCR) (n = 5). (E, F) CD80 and CD86 mRNA levels in liver tissues. (G-I) CD206, ARG-1, and IL-10 mRNA levels in liver tissues. Statistical significance: * vs. control; # vs. IRI; & vs. IRI + G-Exos; % vs. IRI + siRNA@G-Exos (p < 0.05, n = 5)
To further elucidate the hepatoprotective mechanism of siRNA@VG-Exos, we investigated its impact on critical cell death pathways. Automated Western blot analysis (Wes) revealed that siRNA@VG-Exos treatment significantly suppressed the release of cytochrome c (Cyto C) and reduced the protein level of Cleaved Caspase-3 in liver tissues compared to the IRI model group, indicating effective curtailment of the mitochondria-mediated apoptotic pathway (Supplementary Fig. 7 A). Concurrently, the activation of the NLRP3 inflammasome was markedly inhibited at both mRNA and protein levels: protein levels of NLRP3 and IL-1β were prominently downregulated in the IRI + siRNA@VG-Exos group compared with the IRI group (Supplementary Fig. 7 A), and mRNA expressions of NLRP3, ASC, and IL-1β were also significantly decreased Supplementary Fig. 7B), as evidenced by the downregulation of its key components (NLRP3, ASC) and effector (IL-1β). These findings collectively demonstrate that beyond its anti-inflammatory effect, siRNA@VG-Exos confers direct protection against hepatic IRI by simultaneously intervening in both apoptosis and pyroptosis processes.
In terms of endothelial function, siRNA@VG-Exos elicited a significant improvement. We found that the treatment effectively restored nitric oxide (NO) bioavailability in liver tissue and reversed the aberrant upregulation of vascular endothelial growth factor (VEGF) mRNA induced by IRI (Supplementary Fig. 8A-B). These findings suggest a successful correction of the VEGF/NO signaling axis imbalance, thereby improving sinusoidal microcirculation and endothelium-dependent vasoregulation.
Collectively, our results demonstrate that beyond alleviating inflammation in mouse liver ischemia-reperfusion injury by promoting M2 macrophage polarization and inhibiting M1 polarization, siRNA@VG-Exos confers protection through multiple synergistic mechanisms: inhibiting NLRP3 inflammasome activation, modulating both apoptotic and pyroptotic cell death pathways, and ameliorating endothelial dysfunction. This multi-faceted action underpins the comprehensive hepatoprotective effect against IRI.
Multi-omics analyses reveal the anti-inflammatory and antioxidant mechanisms of siRNA@VG-Exos via functional miRNA-mediated regulation and transcriptome remodeling
Transcriptome sequencing comparing IRI + siRNA@VG-Exos and IRI groups identified 276 upregulated and 154 downregulated differentially expressed genes (DEGs) (Fig. 8A). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed significant upregulation of the PPAR signaling pathway and downregulation of TNF signaling, Toll-like receptor signaling, NF-κB signaling, and cytokine production pathways in the IRI + siRNA@VG-Exos group (Fig. 8B-E). Gene Set Enrichment Analysis (GSEA) demonstrated that siRNA@VG-Exos attenuated oxidative stress by suppressing excessive superoxide anion and nitric oxide (NO) generation (Fig. 8F), alleviated inflammation by inhibiting acute inflammatory responses and cytokine-mediated signaling (Fig. 8G), and reduced liver injury through enhanced cell proliferation and suppression of caspase activation cascades (Fig. 8H).
Fig. 8.
Differential gene expression and enrichment analysis (KEGG, GO, GSEA) in liver tissues. RNA sequencing was performed on liver tissues comparing the IRI + siRNA@VG-Exos group with the IRI group. (A) Volcano plot of differentially expressed genes (|Fold Change| ≥ 2, p-value ≤ 0.05, padj ≤ 0.05). (B, C) KEGG pathway enrichment analysis for upregulated (B, top) and downregulated (C, bottom) genes. (D, E) Biological process (BP) terms from GO enrichment analysis for upregulated (D, top) and downregulated (E, bottom) genes. GSEA analysis of key pathways: (F) Oxidative stress pathways: Regulation of superoxide anion generation (top), Regulation of nitric oxide metabolic process (bottom). (G) Inflammatory response pathways: Acute inflammatory response(top), Cytokine-mediated signaling pathway (bottom). (H) Proliferation and apoptosis pathways: Mitotic cell cycle checkpoint signaling (top), Activation of cysteine-type endopeptidase activity involved in apoptotic process (bottom). Statistical significance thresholds for enrichment analyses are indicated within the panels
In vivo safety assessment of siRNA@VG-Exos
The biosafety of intravenously administered G-Exos, siRNA@G-Exos, and siRNA@VG-Exos was evaluated through histopathological examination and serum biochemistry. H&E staining of heart, liver, spleen, lung, and kidney tissues revealed no significant histopathological abnormalities or inflammatory infiltration in any treatment group (Fig. 9A). Serum biochemical markers of renal function (CREA, BUN) and hepatic function (ALT, AST) showed no significant differences compared to the control group (Fig. 9B-E). Co-incubation with erythrocyte suspensions demonstrated no hemolysis or agglutination, with hemolysis rates comparable to controls, confirming excellent blood compatibility (Fig. 9F). These results collectively demonstrate that siRNA@VG-Exos exhibits excellent biocompatibility with minimal tissue toxicity.
Fig. 9.
In vivo safety evaluation of siRNA@VG-Exos. G-Exos, siRNA@G-Exos, or siRNA@VG-Exos were administered via tail vein injection. (A) Histological analysis (H&E staining) of heart, liver, spleen, lung, and kidney tissues from each group. Scale bar = 100 μm. (B, C) Serum creatinine (CREA) and blood urea nitrogen (BUN) levels measured using an automated biochemistry analyzer (n = 3). (D, E) Serum ALT and AST levels measured using an automated biochemistry analyzer. (F) Hemolysis assay of G-Exos, siRNA@G-Exos, and siRNA@VG-Exos. Hemolysis rates are shown. Statistical significance: * vs. Triton X-100 group (n = 3)
Discussion
Hepatic ischemia-reperfusion injury (IRI) occurs in various hepatic surgeries and clinical conditions, such as partial hepatectomy, liver transplantation, and hemorrhagic shock, significantly impacting patient survival and prognosis. However, its molecular mechanisms remain incompletely understood, and effective therapeutic or preventive strategies are lacking [29]. This study synthesized ginseng-derived exosomes modified with the endothelial-targeting peptide VHP and loaded with IL-6 siRNA (siRNA@VG-Exos) to mitigate hepatic IRI. By specifically targeting injured vascular endothelium, siRNA@VG-Exos enhanced the accumulation and release of therapeutic G-Exos components and si-IL6 at the injury site. This approach attenuated oxidative stress, stabilized mitochondrial function, suppressed inflammatory responses, and promoted macrophage M2 polarization, collectively facilitating the repair of damaged hepatic tissue.
Importantly, our study further elucidates the vasculoprotective mechanisms of siRNA@VG-Exos. We demonstrate that siRNA@VG-Exos effectively ameliorates liver sinusoidal endothelial cell (LSEC) dysfunction—a critical pathological event in IRI—through dual pathways: restoring the impaired VEGF/NO signaling axis and suppressing NLRP3 inflammasome activation [30, 31]. Specifically, our formulation reversed the IRI-induced decrease in nitric oxide bioavailability and normalized aberrant VEGF overexpression, thereby improving endothelium-dependent vasodilation. Concurrently, it significantly downregulated key components of the NLRP3 inflammasome and its effector IL-1β, directly mitigating pyroptosis and inflammatory injury in endothelial cells. This coordinated protection of the hepatic microvasculature represents a novel facet of the therapeutic mechanism of siRNA@VG-Exos.
Furthermore, our findings align with the established paradigm that oxidative stress initiates apoptosis during hepatic IRI [32]. Importantly, we further reveal that siRNA@VG-Exos confers comprehensive hepatoprotection via a multi-tiered mechanism: it not only mitigates upstream oxidative stress and inflammation but also directly suppresses the downstream execution of both mitochondrial apoptosis (via inhibition of cytochrome c release and caspase-3 activation) and NLRP3-mediated pyroptosis. This coordinated “anti-oxidant, anti-inflammatory, and anti-death” action underscores the therapeutic potential of siRNA@VG-Exos in simultaneously targeting multiple injury pathways in IRI.
G-Exos have demonstrated therapeutic potential for various diseases, including cancer—such as by modulating immunity to enhance breast cancer treatment [33]—suppressing inflammation to inhibit arthritis progression [34], and promoting regeneration of damaged skin [35]. G-Exos exert these functions by delivering diverse bioactive cargoes, including miRNAs, proteins, and lipids. Studies indicate that G-Exos transport pgi-miR6135j to synovial macrophages, regulating macrophage activity and dampening immune responses to mitigate rheumatoid arthritis [34]. Furthermore, G-Exos alleviate inflammatory diseases by activating cellular autophagy and promoting macrophage M2 polarization, thereby repairing damaged epithelial tissues [36]. In the present study, G-Exos enhanced T-SOD and GSH expression, attenuating oxidative stress damage and restoring mitochondrial function, while concurrently reducing inflammatory responses to exert therapeutic effects.
Accumulating evidence underscores the critical role of macrophage polarization in hepatic ischemia-reperfusion injury (IRI), where excessive macrophage-mediated inflammation is recognized as a key pathogenic driver. Hepatic macrophages polarize into two functionally distinct phenotypes: pro-inflammatory M1 macrophages that exacerbate injury and anti-inflammatory M2 macrophages that promote resolution [10, 37]. Hepatic IRI induces M1 polarization, triggering secretion of pro-inflammatory cytokines (e.g., IL-6, TNF-α), upregulation of endothelial adhesion molecules, and induction of hepatocyte chemokine expression, collectively amplifying inflammatory cascades [10]. Studies in liver transplantation models demonstrate that macrophages overexpressing heme oxygenase-1 (HO-1) suppress neutrophil infiltration and enhance IL-10 production to mitigate liver damage. In this study, VHP-siIL6@G-Exos therapy promoted IL-10 expression and M2 macrophage activation, facilitating the repair of injured hepatic tissue.
The delivery and cellular uptake efficiency of naked siRNA is limited, as it cannot passively diffuse into cells and undergoes rapid enzymatic degradation followed by plasma clearance and renal elimination. Exosomes-mediated siRNA delivery effectively overcomes these limitations [21]. Exosomes possess high biocompatibility, enhanced stability, and low immunogenicity, offering significant advantages over conventional synthetic nanocarriers as drug delivery systems [38]. G-Exos exhibit excellent biocompatibility and stability [20], as validated in this study by zeta potential measurements and biosafety assessments of siRNA@VG-Exos. Thus, exosomes-mediated delivery of IL-6-targeting siRNA protects the therapeutic cargo from degradation while ensuring efficacy. Concurrently, G-Exos inherently contain bioactive ginseng components that mitigate hepatic IRI through anti-inflammatory, antioxidant, and anti-apoptotic mechanisms [14, 18, 39]. By delivering IL-6-targeting siRNA, G-Exos synergistically enhance anti-inflammatory effects to promote hepatic repair.
Studies indicate that the VHP peptide exhibits high affinity for injured endothelium. Compared to non-VCAM-1-targeting peptide nanoparticles, VHP modification significantly enhances nanoparticle binding to endothelial VCAM-1, increasing diagnostic sensitivity for early atherosclerotic plaques [26]. Furthermore, MRI studies demonstrate that VCAM-1-targeted contrast agents effectively accumulate in the knee joints of rheumatoid arthritis (RA) mice, facilitating early RA diagnosis [28]. Sinusoidal endothelial cell injury is also a critical pathogenic mechanism in hepatic IRI. In this study, we employed the endothelial-targeting peptide VHPKQHR (Val-His-Pro-Lys-Gln-His-Arg) to enhance the targeting capability of G-Exos to injured organs. In vivo animal imaging confirmed significant enrichment of VHP-G-Exos within liver tissue. This targeted delivery promotes the effective accumulation and site-specific release of si-IL6-loaded G-Exos at the injury site.
The G-Exos platform utilized in this study represents a paradigm shift from conventional delivery systems, offering advantages rooted in its unique biological origin. First, unlike synthetic lipid nanoparticles (LNPs) that serve primarily as passive carriers, G-Exos are naturally loaded with therapeutic cargoes such as ginsenosides and miRNAs, providing inherent anti-inflammatory and antioxidant activities that synergize with the delivered si-IL-6 for a multi-mechanistic attack on IRI pathology [40]. Second, as plant-derived vesicles, G-Exos exhibit superior biocompatibility and a lower risk of immune activation compared to their mammalian counterparts (e.g., MSC-Exos) [40, 41], a claim strongly supported by our in vivo safety assessment (Fig. 9). Finally, the platform addresses key translational challenges: the widespread availability of ginseng and standardized isolation methods circumvent the scalability and batch-to-batch consistency issues often associated with cell culture-derived exosomes. Therefore, G-Exos emerge not simply as a delivery vehicle, but as an active, safe, and scalable therapeutic partner.
Limitation
The current study has several limitations that should be acknowledged. The findings are primarily derived from murine models and the RAW264.7 cell line, and their translational relevance remains to be validated in human-derived systems or clinically relevant models. Furthermore, comprehensive evaluations of the long-term biosafety, immunogenicity, and scalable production processes of siRNA@VG-Exos are still required. To address these limitations, future research will focus on validating therapeutic efficacy in more physiologically relevant human models, such as organoids, conducting systematic non-clinical safety and pharmacokinetic studies, establishing GMP-compliant manufacturing processes, and exploring the therapeutic potential of this delivery platform in other pathologies characterized by VCAM-1 upregulation and IL-6 overproduction, such as atherosclerosis.
Conclusion
siRNA@VG-Exos mitigates murine hepatic ischemia-reperfusion injury by targeting damaged liver tissue, promoting macrophage M1-to-M2 polarization to suppress inflammatory responses, reducing oxidative stress damage, and regulating metabolic pathways. These findings suggest a novel therapeutic strategy for clinically managing liver failure post-hepatectomy and graft dysfunction post-transplantation associated with hepatic IRI.
Method
Animal experiment
Male C57BL/6J mice (6–8 weeks old) were obtained from Charles River Laboratories. All mice were housed under specific pathogen-free (SPF) conditions with ad libitum access to food and water in accordance with ethical standards. All procedures complied with ethical guidelines approved by the Institutional Animal Care and Use Committee, Sun Yat-Sen University (Approval No. SYSU-IACUC-2024–003041).
Extraction of ginseng exosomes
Fresh ginseng roots were sequentially washed with tap water, distilled water, and 1× phosphate-buffered saline (PBS) to remove turbid impurities. The cleaned roots were cut into small pieces and homogenized using a blender. Following a previously reported protocol [42], the homogenate underwent sequential centrifugation steps: 400 × g for 20 min, 800 × g for 20 min, and 15,000 × g for 20 min. The supernatant collected after these steps was then subjected to ultracentrifugation at 100,000 × g for 1 h. The resulting pellet was resuspended and further purified by sucrose density gradient centrifugation (using layers of 1 M and 2 M sucrose solutions) at 150,000 × g for 3 h at 4 °C. The exosome-enriched fraction located at the interface between the sucrose layers was collected as G-Exos. The collected G-Exos were washed with PBS, and the protein concentration was determined.
Preparation and characterization of siRNA@VG-Exos
siRNA@G-Exos were prepared by electroporating si-IL6 into G-Exos. VHP was then conjugated to siRNA@G-Exos using an endothelial-targeting peptide-lipid anchor kit (ExoBrooch™ Kit) to generate siRNA@VG-Exos. The morphology of G-Exos, siRNA@G-Exos, and siRNA@VG-Exos was visualized by negative staining transmission electron microscopy (TEM) using a Titan Krios G4 microscope. The size distribution and concentration of the various exosome preparations were assessed using NanoSight nanoparticle tracking analysis (Malvern Panalytical). The zeta potential values of the exosomes were measured using a Zeta potential analyzer (Anton Paar).
Stability assessment of siRNA@VG-Exos
siRNA@VG-Exos were incubated at 4 °C and 37 °C. Changes in their size distribution over days 1 to 7 were monitored using NanoSight nanoparticle tracking analysis (Malvern Panalytical).
Analysis of Long-term and Temperature-Dependent release kinetics of EV-Encapsulated SiRNA
To systematically evaluate the long-term stability and release kinetics of extracellular vesicle (EV)-encapsulated 5-FAM-labeled siRNA, samples were incubated in PBS at both 4 °C and 37 °C, with aliquots collected at days 1, 2, 3, 5, and 7. At each time point, samples were processed using a 100 kDa centrifugal filter to separate released components. The cumulative release percentage was accurately determined by measuring the 5-FAM fluorescence in the filtrate, followed by recovery correction. This approach allowed for the direct comparison of release profiles and stability under the two temperature conditions.
Cost analysis
The methodological approach for the lipidomic profiling is outlined as follows. Lipid analysis of ginseng-derived exosomal vesicles was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Briefly, exosomes were isolated from ginseng samples, followed by lipid extraction. The extracted lipids were separated by chromatographic elution, ionized via an electrospray ionization (ESI) source, and subsequently scanned and analyzed by the mass spectrometer.
MiRNA target gene functional analysis
Differentially expressed miRNAs were identified through small RNA sequencing, and a heatmap was generated to visualize highly expressed miRNAs. Potential target genes were predicted using bioinformatic tools such as TargetScan. These target genes were subsequently subjected to KEGG pathway enrichment analysis and Gene Ontology (GO) functional annotation. Key significantly enriched pathways and functional terms were visualized using bubble plots.
SiRNA loading efficiency and in vivo gene Silencing efficacy assessment
The siRNA loading efficiency was determined using the RiboGreen fluorescence assay. To systematically evaluate the in vivo gene silencing efficacy of siRNA@VG-Exos, we established a murine hepatic ischemia-reperfusion injury model for dual-dimensional dose-time analysis. For dose-response assessment, mice received intravenous injections of siRNA@VG-Exos at escalating doses (0–2 mg/kg) with liver tissues collected 6 h post-administration. For time-course evaluation, mice were administered 0.5 mg/kg siRNA@VG-Exos and liver tissues were harvested at serial time points (0, 1, 3, 6, and 12 h) post-injection. Hepatic IL-6 mRNA expression was quantified by RT-qPCR with GAPDH normalization.
Cell culture and establishment of the cellular H/R model
RAW264.7 cells (RAW) (Procell, Wuhan, China) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂. To establish the cellular H/R model, cells at 60–70% confluence were incubated in FBS-free and glucose-free DMEM under hypoxic conditions (1% O₂, 5% CO₂, 94% N₂) for 6 h, followed by reoxygenation under normoxic conditions (21% O₂, 5% CO₂) for 12 h.
Exosome uptake assay
RAW cells were incubated with DiO-labeled exosomes under one of the following conditions: (1) at 4 °C, or (2) after pre-treatment with endocytosis inhibitors Filipin (10 µg/mL, Macklin) or Chloroquine (50 µM, Macklin) for 30 min at 37 °C. The uptake efficiency of exosomes by RAW cells was subsequently analyzed using flow cytometry.
Enzyme-Linked immunosorbent assay (ELISA) and automated biochemistry
Levels of malondialdehyde (MDA), total superoxide dismutase (T-SOD), catalase (CAT), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) were measured using the following ELISA kits according to the manufacturers’ instructions: MDA Assay Kit (Servicebio, G4300-96T), T-SOD Assay Kit (Servicebio, G4306-96T), CAT Assay Kit (Servicebio, G4307-96T), IL-6 ELISA Kit (Servicebio, GEM0001-96T), TNF-α ELISA Kit (Servicebio, GEM0004-96T), and IL-1β ELISA Kit (Servicebio, GEM0002-96T). Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), and blood urea nitrogen (BUN) were automatically determined using a Chemray 240 automated biochemistry analyzer (Rayto Life and Analytical Sciences Co., Ltd., Shenzhen, China).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA was extracted using a chloroform substitute (Servicebio, G3014). Reverse transcription reactions were performed using a commercial kit (Servicebio, G3337). For each reverse transcription product, triplicate qPCR reaction mixtures were prepared. Amplification was carried out on a real-time PCR instrument. Data analysis utilized the ΔΔCT method. The following primers were used for RT-qPCR:
IL-6(S: CATAGCTACCTGGAGTACATGAAGAA, A: GACTCCAGCTTATCTCTTGGTTGA),
IL-12(S: CACTGCTGCTGAAATCTTCTCAC, A: ACTGAGGTGGTTTAGGAGGGC),
Arg1(S: GGTGGCAGAGGTCCAGAAGAA, A: CCCATGCAGATTCCCAGAGC),
Mrc1(S: GGAGTGGCAGGTGGCTTATG, A: CACTGCTCGTAATCAGCCTCC),
YM1(S: ATACCAGTTGGGCTAAGGACAG, A: TCCAAACTTCCATCCTCCAAT),
TNF-α(S: AGCACAGAAAGCATGATCCG, A: CACCCCGAAGTTCAGTAGACA),
IL-1β(S: AAATGCCACCTTTTGACAGTGA, A: AAAGAAGGTGCTCATGTCCTCATCC),
iNOS(S: CACCTTGGAAGAGGAGCAACTAC, A: GAGCAAAGGCGCAGAACTGA),
IL-10(S: AATAAGCTCCAAGACCAAGGTGT, A: CATCATGTATGCTTCTATGCAGTTG),
NLRP3(S: CAGCGATCAACAGGCGAGAC, A: AGAGATATCCCAGCAAACCTATCCA),
ASC(S: CTAGTTTGCTGGGGAAAGAAC, A: CTAAGCACAGTCATTGTGAGCTC),
IL-1β(S: ACAGCAGCACATCAACAAGAG, A: CCAGCAGGTTATCATCATCATCC),
VEGF(S: TGCAGATTATGCGGATCAAACC, A: TGCATTCACATTTGTTGTGCTGTAG)
GAPDH(S: CCTCGTCCCGTAGACAAAATG, A: TGAGGTCAATGAAGGGGTCGT).
Immunofluorescence staining (BrdU)
Cells grown on coverslips within culture plates were incubated with primary antibodies specific for the target antigens: CD206 (Servicebio, GB113497-100), CD86 (Servicebio, GB13585), and BrdU (Servicebio, GB12051-100). Subsequently, appropriate fluorescently labeled secondary antibodies (Servicebio) were applied. Images were acquired using fluorescence microscopy at their respective characteristic emission wavelengths.
Flow cytometry
Cells were stained using the following reagents: a fluorescent probe for reactive oxygen species (ROS) detection (DCFH-DA, MeilunBio, MA0219), the APC Annexin V Apoptosis Detection Kit with 7-AAD (Tonbo Biosciences), and the JC-1 Mitochondrial Membrane Potential Assay Kit (Beyotime, C2003S). Stained cells were analyzed on a BECKMAN flow cytometer according to standard instrument operating protocols and experimental procedures. Data analysis was performed using FlowJo software.
Hepatic Ischemia-Reperfusion injury (IRI) animal model
Male C57 mice (6–8 weeks old) were randomly divided into five experimental groups: Sham, IRI + PBS, IRI + si-IL6, IRI + G-Exos, and IRI + siRNA@VG-Exos. Predefined exclusion criteria included intraoperative mortality, failure of ischemia/reperfusion induction (e.g., inadequate vascular occlusion or reperfusion), systemic compromise (such as hypothermia or lethargy), and technical issues during sample processing; no animals were excluded based on these criteria.
Mice were anesthetized via intraperitoneal injection of sodium pentobarbital (80 mg/kg). The abdominal fur was shaved, and mice were placed on a heating pad to maintain core body temperature at 32 °C. A midline laparotomy was performed to access the abdominal cavity. Blood flow to the left and median liver lobes was interrupted by applying a microvascular clamp to the hepatic artery and portal vein for 1 h. The clamp was then removed, and siRNA@VG-Exos were administered intravenously (or via the specified route). Sham-operated mice underwent identical procedures, excluding vascular occlusion and vesicle administration. Following 2 h of reperfusion, mice were euthanized in accordance with ethical guidelines. Blood was collected via cardiac puncture, and liver tissue samples were harvested.
Validation of VCAM-1–Dependent liver targeting: in vivo and ex vivo fluorescence imaging with VHP Pre-Blocking
To determine whether the targeted accumulation of siRNA@VG-Exos in ischemic liver regions depends on the interaction between the VHP peptide and VCAM-1, a VHP pre-blocking experimental group was established. In this group, siRNA@VG-Exos were pre-incubated with recombinant VCAM-1 protein to competitively block their targeting capability. Subsequently, DIR-labeled siRNA@VG-Exos (experimental group) and VCAM-1–pre-blocked siRNA@VG-Exos (blocked group) were administered separately to mice with hepatic ischemia–reperfusion injury via tail vein injection. Whole-body fluorescence imaging was performed using a small animal in vivo optical imaging system at 0, 6, 12, and 24 h post-injection to dynamically monitor and compare fluorescence signal intensity in the liver region between the two groups. At 24 h post-injection, mice were euthanized, and the heart, liver, spleen, lungs, and kidneys were collected for ex vivo organ fluorescence imaging to evaluate the distribution differences of DIR-labeled exosomes in major organs.
Automated Western blot analysis (Wes)
To quantitatively assess the expression levels of key proteins involved in apoptosis and pyroptosis pathways in liver tissues, we performed protein expression analysis using the Wes automated protein analysis system. Denatured protein samples, corresponding primary antibodies, fluorescently labeled secondary antibodies, and reagents were sequentially loaded into the assay plate. The Wes instrument automatically executed capillary electrophoresis, immunoprobing, and chemiluminescent signal detection. The primary antibodies used were as follows: cytochrome C (HUABIO, ET1610-60), Cleaved Caspase-3 (HUABIO, ET1608-64), NLRP3 (HUABIO, ET1610-93), and IL-1β (HUABIO, HA601002). All target protein expressions were normalized to β-actin as an internal reference.
Measurement of nitric oxide metabolites
The concentration of nitric oxide metabolites in liver tissue was determined by measuring nitrite content using a Nitric Oxide Assay Kit (Beyotime, S0023). The supernatant of liver tissue homogenate was subjected to the Griess reaction, and absorbance was measured at 540 nm using a microplate reader. Nitrite concentration was calculated based on a sodium nitrite standard curve and normalized to protein content per microgram of tissue.
Histological staining
Hematoxylin and Eosin (H&E) Staining: Paraffin-embedded liver sections were stained with hematoxylin and eosin (H&E). Liver injury was assessed using the Suzuki scoring system (score range 0–4) based on the H&E-stained Sect [4].
Immunofluorescence (IF) Staining (TUNEL): Paraffin sections were incubated with a primary antibody against TUNEL (Servicebio, GDP1043), followed by incubation with a fluorescently labeled secondary antibody (Servicebio). TUNEL-positive cells (indicating apoptosis) were visualized using confocal microscopy.
Immunohistochemistry (IHC) Staining (Ki67): Sections were incubated with a primary antibody against Ki67 (Servicebio, GB111499-50), followed by incubation with an appropriate secondary antibody (Servicebio). Ki67-positive cells (indicating proliferation) were detected using conventional light microscopy.
In vivo and ex vivo fluorescence imaging
To monitor the biodistribution of siRNA@VG-Exos and siRNA@G-Exos in vivo, mice received an intravenous (tail vein) injection of exosomes labeled with the lipophilic fluorescent tracer DiR immediately following hepatic ischemia-reperfusion. Labeling was performed by incubating precipitated siRNA@VG-Exos or siRNA@G-Exos with DiR at room temperature in the dark for 15 min. DiR-labeled exosomes were purified by ultracentrifugation (and washed with PBS). Whole-body fluorescence images visualizing the distribution of siRNA@VG-Exos and siRNA@G-Exos were acquired at 1 h, 2 h, 4 h, 6 h, and 12 h post-injection using a small animal optical imaging system (Revvity). Finally, mice were euthanized, and the heart, liver, spleen, lungs, and kidneys were excised. The distribution of the labeled exosomes within these isolated organs was quantified ex vivo using the same imaging system.
Hepatocyte transcriptome sequencing and analysis
Liver tissue samples were collected and subjected to RNA sequencing (RNA-seq) performed by Anoroad Gene Technology (Beijing) Co., Ltd. The obtained gene expression levels were first analyzed for differential expression, applying the thresholds of |Fold Change| ≥ 2, p-value ≤ 0.05, and adjusted p-value (padj) ≤ 0.05. Following the identification of differentially expressed genes (DEGs), the DEG sets were subjected to Gene Ontology (GO) functional enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and Gene Set Enrichment Analysis (GSEA) using the ClusterProfiler software package in R.
Statistical analysis
All data are presented as the mean ± standard deviation (SD). Comparisons between two groups were performed using the unpaired Student’s t-test. Comparisons among multiple groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple comparisons. Statistical significance was set at P < 0.05. All statistical analyses were conducted using GraphPad Prism software.
Supplementary Information
Acknowledgements
We thank Sijia Lei at the Revvity for her technical support in the experiment of IVIS Spectrum.
Author contributions
K.H., X.Z. and X.Y. contributed equally to this work. K.H., X.Z. and X.Y. are responsible for the completion of the main experiment and writing the original manuscript. Z. F., H. Y., C. W., and J. M. are responsible for the design of the project and providing financial support. Other staff completed some experiment, and reviewed and modified the manuscript. The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.
Funding
Project ZR2022QH331 supported by Shandong Provincial Natural Science, Jining Public Health Medical Center High-level Talent Research Foundation (NO. JGW2024GCC001). Shandong Province Medical and Health Science and Technology Project(202403080414,202420000422, 202311001413);Research program of Medical and Health Science and Technology Development Plan Project of Shandong Province (202103080729); National Natural Science Foundation of China (grant no. 82360837); Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation (grant no. 2022JJA141119); First-class discipline innovation-driventalent program of Guangxi Medical University (Chunming Wang).
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Declarations
Ethics approval and consent to participate
The procedure of animal experiments was approved by the Institutional Animal Care and Use Committee, Sun Yat-Sen University (Approval No. SYSU-IACUC-2024-003041).
Consent for publication
All authors have given approval to the final version of the manuscript.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Kaijun Huang, Xuanlin Zhang and Xufeng Yan contributed equally to this work.
Contributor Information
Haoxiang Yuan, Email: 2024390294@gzhmu.edu.cn.
Zhijin Fan, Email: fanzhijin@m.scnu.edu.cn.
Chunming Wang, Email: wangchm27@alumni.sysu.edu.cn.
Jian Ma, Email: majian7@alumni.sysu.edu.cn.
References
- 1.Fang B, Yang J, Wang L, Li H, Guo J, Zhang J, et al. A mitochondria-targeted h2s-activatable fluorogenic probe for tracking hepatic ischemia-reperfusion injury. Chin Chem Lett. 2024;35(6):108913. [Google Scholar]
- 2.Saidi RF, Kenari S. Liver ischemia/reperfusion injury: an overview. J Invest Surg. 2014;27(6):366–79. [DOI] [PubMed] [Google Scholar]
- 3.Zhang Y, Yang ZC, Zhou QH, Geng ZY, Huang KJ, Yang Y, et al. Lipid metabolism-related genes regulate the immune microenvironment during ex vivo lung perfusion for lung transplants. J Thorac Dis. 2025;17(8):6045–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li SL, Wang ZM, Xu C, Che FH, Hu XF, Cao R, et al. Liraglutide attenuates hepatic ischemia-reperfusion injury by modulating macrophage polarization. Front Immunol. 2022;13:869050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Du S, Zhang X, Jia Y, Peng P, Kong Q, Jiang S, et al. Hepatocyte hspa12a inhibits macrophage chemotaxis and activation to attenuate liver ischemia/reperfusion injury via suppressing glycolysis-mediated hmgb1 lactylation and secretion of hepatocytes. Theranostics. 2023;13(11):3856–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Xia K, Wang T, Chen Z, Guo J, Yu B, Chen Q, et al. Hepatocellular setdb1 regulates hepatic ischemia-reperfusion injury through targeting lysine methylation of ask1 signal. Research. 2023;6:0256. 10.34133/research.0256 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nakamura K, Zhang M, Kageyama S, Ke B, Fujii T, Sosa RA, et al. Macrophage heme oxygenase-1-sirt1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. J Hepatol. 2017;67(6):1232–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hu Y, Zhan F, Wang Y, Wang D, Lu H, Wu C, et al. The ninj1/dusp1 axis contributes to liver ischemia reperfusion injury by regulating macrophage activation and neutrophil infiltration. Cell Mol Gastroenterol Hepatol. 2023;15(5):1071–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ye L, He S, Mao X, Zhang Y, Cai Y, Li S. Effect of hepatic macrophage polarization and apoptosis on liver ischemia and reperfusion injury during liver transplantation. Front Immunol. 2020;11:1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wang H, Xi Z, Deng L, Pan Y, He K, Xia Q. Macrophage polarization and liver ischemia-reperfusion injury. Int J Med Sci. 2021;18(5):1104–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhang J, Yan J, Wang Y, Liu H, Sun X, Gu Y, et al. Restoring cellular calcium homeostasis to rescue er stress by 1,2-bis(2-aminophenoxy)ethane-n,n,n′,n′-tetraacetic acid acetoxymethyl ester-loaded lipid-mplga hybrid-nanoparticles for acute kidney injury therapy. Chin Chem Lett. 2024;35(3):108434. [Google Scholar]
- 12.Zhang Y, Wu D, Zhou C, Bai M, Wan Y, Zheng Q, et al. Engineered extracellular vesicles for tissue repair and regeneration. Burns Trauma. 2024;12:tkae062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Carlson K, Kink J, Hematti P, Al-Adra DP. Extracellular vesicles as a novel therapeutic option in liver transplantation. Liver Transpl. 2020;26(11):1522–31. [DOI] [PubMed] [Google Scholar]
- 14.Shen P, Huang K, Zhang X, Yin G, Qin M, Ma H, et al. Genetically engineered msc-derived hybrid cellular vesicles for ros-scavenging and mitochondrial homeostasis in hepatic ischemia-reperfusion injury. Mater Today Bio. 2025;34:102215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wu R, Fan X, Wang Y, Shen M, Zheng Y, Zhao S, et al. Mesenchymal stem cell-derived extracellular vesicles in liver immunity and therapy. Front Immunol. 2022;13:833878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zheng J, Lu T, Zhou C, Cai J, Zhang X, Liang J, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect liver ischemia/reperfusion injury by reducing cd154 expression on cd4 + t cells via cct2. Adv Sci. 2020;7(18):1903746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Yang C, Yao L, Zhang L. Silk sericin-based biomaterials shine in food and pharmaceutical industries. Smart Mater Med. 2023;4:447–59. [Google Scholar]
- 18.Elsayed Abouzed DE, Ezelarab HAA, Selim H, Elsayed MMA, El Hamd MA, Aboelez MO. Multimodal modulation of hepatic ischemia/reperfusion-induced injury by phytochemical agents: a mechanistic evaluation of hepatoprotective potential and safety profiles. Int Immunopharmacol. 2024;138:112445. [DOI] [PubMed] [Google Scholar]
- 19.Ye Y, Liu Y, Ma S, Li X, Wang W, Chen X, et al. Multifunctional DNA hydrogels with light-triggered gas-therapy and controlled g-exos release for infected wound healing. Bioact Mater. 2025;52:422–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kim J, Zhang S, Zhu Y, Wang R, Wang J. Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines. J Ginseng Res. 2023;47(5):627–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138–50. [DOI] [PubMed] [Google Scholar]
- 22.Antimisiaris S, Mourtas S, Papadia K. Targeted si-RNA with liposomes and exosomes (extracellular vesicles): how to unlock the potential. Int J Pharm. 2017;525(2):293–312. [DOI] [PubMed] [Google Scholar]
- 23.Kaltenmeier C, Wang R, Popp B, Geller D, Tohme S, Yazdani HO. Role of immuno-inflammatory signals in liver ischemia-reperfusion injury. Cells. 2022;11(14):2222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kim D, Nam SS, Jeon H, Cho Y, Sim E, Kim H. Phospholipid-based nanodrill technology for enhanced intracellular delivery of nano-sized cargos. Smart Mater Med. 2023;4:493–503. [Google Scholar]
- 25.Zhou Z, Yeh CF, Mellas M, Oh MJ, Zhu J, Li J, et al. Targeted polyelectrolyte complex micelles treat vascular complications in vivo. Proc Natl Acad Sci U S A. 2021;118(50):92114842118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Xu W, Zhang S, Zhou Q, Chen W. Vhpkqhr peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions. Artif Cells Nanomed Biotechnol. 2019;47(1):2440–8. [DOI] [PubMed] [Google Scholar]
- 27.Huang C, Huang W, Zhang L, Zhang C, Zhou C, Wei W, et al. Targeting peptide, fluorescent reagent modified magnetic liposomes coated with Rapamycin target early atherosclerotic plaque and therapy. Pharmaceutics. 2022;14(5):1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhang C, Huang W, Huang C, Zhou C, Tang Y, Wei W, et al. Vhpkqhr peptide modified ultrasmall paramagnetic iron oxide nanoparticles targeting rheumatoid arthritis for T(1)-weighted magnetic resonance imaging. Front Bioeng Biotechnol. 2022;10:821256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Liu Y, Lu T, Zhang C, Xu J, Xue Z, Busuttil RW, et al. Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. J Hepatol. 2019;71(4):719–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Penna C, Pagliaro P. Endothelial dysfunction: redox imbalance, NLRP3 inflammasome, and inflammatory responses in cardiovascular diseases. Antioxidants (Basel). 2025;14(3):256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yinzhi D, Jianhua H, Hesheng L. The roles of liver sinusoidal endothelial cells in liver ischemia/reperfusion injury. J Gastroenterol Hepatol. 2024;39(2):224–30. [DOI] [PubMed] [Google Scholar]
- 32.Cavalieri B, Perrelli MG, Aragno M, Mastrocola R, Corvetti G, Durazzo M, et al. Ischemic preconditioning attenuates the oxidant-dependent mechanisms of reperfusion cell damage and death in rat liver. Liver Transpl. 2002;8(11):990–9. [DOI] [PubMed] [Google Scholar]
- 33.Yu Y, Duan X, Wang X, Yang M, Weng L, Li D, et al. Enhanced therapeutic effects of ginseng-derived exosome-like nanoparticles loaded hyaluronic acid injectable hydrogels for breast tumor treatment. Int J Biol Macromol. 2025;310(Pt 3):142914. [DOI] [PubMed] [Google Scholar]
- 34.Wang X, Liu H, Fan H, Han B, Ye H, Ye X, et al. Ginseng exosomal mirna ameliorates rheumatoid arthritis by mediating kras-mapk signaling. Int Immunopharmacol. 2025;161:115046. [DOI] [PubMed] [Google Scholar]
- 35.Park HY, Kang MH, Lee G, Kim JW. Enhancement of skin regeneration through activation of tgf-β/smad signaling pathway by Panax ginseng Meyer non-edible callus-derived extracellular vesicles. J Ginseng Res. 2025;49(1):34–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Yang S, Fan L, Yin L, Zhao Y, Li W, Zhao R, et al. Ginseng exosomes modulate m1/m2 polarisation by activating autophagy and target ikk/iкb/nf-кb to alleviate inflammatory bowel disease. J Nanobiotechnol. 2025;23(1):198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Konishi T, Lentsch AB. Hepatic ischemia/reperfusion: mechanisms of tissue injury, repair, and regeneration. Gene Expr. 2017;17(4):277–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Yuan HX, Ye YY, Shen P, Zhang J, Meng QF, Chen Y, et al. Engineering neutrophil vesicles for synergistic protection against ischemia/reperfusion injury after lung transplant. Adv Sci. 2025. 10.1002/advs.202506127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Han X, Zheng W, Sun Z, Luo T, Li Z, Lai W, et al. Plant-derived exosomes: unveiling the similarities and disparities between conventional extract and innovative form. Phytomedicine. 2025;145:157087. [DOI] [PubMed] [Google Scholar]
- 41.Li S, Cai X, Guo J, Li X, Li W, Liu Y, et al. Cell communication and relevant signaling pathways in osteogenesis-angiogenesis coupling. Bone Res. 2025;13(1):45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Yang S, Li W, Bai X, Di Nunzio G, Fan L, Zhao Y, et al. Ginseng-derived nanoparticles alleviate inflammatory bowel disease via the TLR4/MAPK and p62/NRF2/KEAP1 pathways. J Nanobiotechnol. 2024;22(1):48. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.









